Medicines for rare diseases and severe sepsis

Summary

Fundeni Clinical Institute is procuring medicines for rare diseases and severe sepsis under a 36-month framework agreement. The two lots cover sebelipase alfa, 2 mg/ml in 10 ml packs (2,376–7,128 units), and eculizumab, 300 mg (5,400–16,200 units). The total maximum framework value is RON 429,770,519.28.